Switching to Tresiba(R) is Highly Cost-effective and Cost-saving in a Real-world Setting

PR70874

GLASGOW, Scotland, Nov. 6, 2017 /PRNewswire=KYODO JBN/ --

    Poster Presentation PDB27

    A new analysis of real-world data has shown that switching to Tresiba(R)

(insulin degludec) is highly cost-effective and cost-saving for the treatment

of type 1 and type 2 diabetes, respectively.[1] The analysis was presented

today at the International Society for Pharmacoeconomics and Outcomes Research

(ISPOR 2017) 20th Annual European Congress.

    Tresiba(R) remained cost-effective even after excluding key benefits

associated with switching to Tresiba(R) such as reductions in hypoglycaemia

(low blood sugar levels) and the use of health system resources in a

calculation based on a treatment period of one year. When estimating the

lifetime cost of diabetes, cost savings were even greater.[1]

    These data build on previously reported real-world evidence which found

that switching to Tresiba(R) from other basal insulins, mainly insulin glargine

U100 and insulin detemir, provides significant reductions in blood glucose

levels, as well as lowering the rates of potentially dangerous severe

hypoglycaemic episodes by 92% in people with type 2 diabetes and by 85% in

people with type 1 diabetes.[2][3]

    "In addition to the body of evidence supporting its benefits in clinical

practice, Tresiba(R) has been shown to be a cost-effective treatment option

across various European healthcare systems," said Mads Krogsgaard Thomsen,

executive vice president and chief science officer at Novo Nordisk. "We hope

these encouraging findings from real-world clinical practice will help make

Tresiba(R) available to even more people living with type 1 and type 2 diabetes

around the world."

    About the analysis  

This new analysis was based on an Italian subpopulation of the EU-TREAT

(EUropean TREsiba AudiT) study, which is a European, multicentre, real-world

evidence study with 2,550 people, investigating the effect of switching to

Tresiba(R) from another basal insulin in people with type 1 and type 2

diabetes.[1-3]

    Cost-effectiveness was evaluated based on change in hypoglycaemia rates,

basal and prandial insulin dose, and body weight at 6 months after switching to

Tresiba(R) in 397 people with type 1 and 153 people with type 2 diabetes from

Italy. Cost-effectiveness models evaluated the incremental cost-effectiveness

ratio (ICER) for cost per quality-adjusted life year (QALY)[1] and enable

comparisons to be made across treatments and therapy areas.

    About Tresiba(R)

Tresiba(R) (insulin degludec) is a once-daily basal insulin that provides

duration of action beyond 42 hours with a flat and stable glucose-lowering

effect.[4],[5] It provides low variability in blood glucose levels and a lower

risk of overall, nocturnal and severe hypoglycaemia vs. insulin glargine

U100.[4],[6] On occasions when administration at the same time of day is not

possible, Tresiba(R) allows for flexibility in day-to-day dosing

time with a minimum of eight hours between injections.[4] Tresiba(R) received

its first regulatory approval in September 2012 and has since been approved in

more than 80 countries globally. It is now commercially available in more than

50 countries.

    About Novo Nordisk    

Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat obesity,

haemophilia, growth disorders and other serious chronic conditions.

Headquartered in Denmark, Novo Nordisk employs approximately

41,700 people in 77 countries, and markets its products in more than 165

countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).

Its ADRs are listed on the New York Stock Exchange (NVO). For more information,

visit www.novonordisk.com [http://www.novonordisk.com ], Facebook

[http://www.facebook.com/novonordisk ], Twitter

[http://www.twitter.com/novonordisk ], LinkedIn

[http://www.linkedin.com/company/novo-nordisk ], YouTube

[http://www.Youtube.com/novonordisk ].  

    Further information

    References   

    1. Haldrup S, Lapolla A, Gundgaard J, et al. Cost-effectiveness of

switching to insulin degludec (ideg) in real-world clinical practice in italy.

Poster presentation. International Society for Pharmacoeconomics and Outcomes

Research (ISPOR) 20th Annual European Congress, Glasgow, Scotland. November

2017.

    2. Siegmund T, Tentolouris N, Knudsen TS, et al. EU-TREAT 1: Switching to

insulin degludec reduces the risk of hypoglycaemia in patients with T1DM in a

real-world setting. Poster presentation. 77th Annual Scientific Sessions of the

American Diabetes Association (ADA), San Diego, California, US. June 2017.

    3. Schultes B, Tentolouris N, Knudsen TS, et al. EU-TREAT 2: Switching to

insulin degludec improves glycaemic control in patients with T2DM in a

real-world setting. Poster presentation. 77th Annual Scientific Sessions of the

American Diabetes Asosciation (ADA), San Diego, California, US. June 2017.

    4. EMA. Tresiba(R) Summary of Product Characteristics. Available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf.

Last accessed: October 2017.

    5. Haahr H, Heise T. A review of the pharmacological properties of insulin

degludec and their clinical relevance. Clin Pharmacokinet. 2014; 53:787-800.

    6. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec

versus glargine in type 2 diabetes. N Engl J Med. 2017; 377:723-732.

    Novo Nordisk A/S  

    Corporate Affairs

    Novo Alle

    2880 Bagsvaerd

    Denmark

    Telephone:

    +45-4444-8888

    Internet:

    www.novonordisk.com

    CVR no:

    24 25 67 90

    ZINC#: HQMMA/TB/1017/0371 November 2017

    Further information

    Media:

    Katrine Sperling

    +45-4442-6718

    krsp@novonordisk.com

    Asa Josefsson

    +45-3079-7708

    aajf@novonordisk.com

    Investors:

    Peter Hugreffe Ankersen

    +45-3075-9085

    phak@novonordisk.com

    Hanna Ogren

    +45-3079-8519

    haoe@novonordisk.com

    Anders Mikkelsen

    +45-3079-4461

    armk@novonordisk.com

    Christina Kjaer

    +45-3079-3009

    cnje@novonordisk.com

    Kasper Veje (US)

    +1-609-235-8567

    kpvj@novonordisk.com

Source: Novo Nordisk